Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02353351 · ClinicalTrials.gov registry record
ADVANCE ASO AMPLATZER™ Atrial Septal Occluder Post Market Surveillance Study
A clinical trial, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- 602
- Enrollment target
NCT02353351: Clinical Trial study, sponsored by Abbott Medical Devices.
NCT02353351 is a clinical trial that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 602 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02353351 was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- 602 participants
- Enrollment target
Study Summary
Prospective, multicenter, case-cohort study.To identify potential risk factors associated with the occurrence of erosion due to implantation of the AMPLATZER™ Septal Occluder (ASO.)
Primary Outcome
Cumulative incidence of erosion will be reported as: • The number of erosions per 8000 subjects.
Interventions
- DEVICE atrial septal occluder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2015-01-19 |
| Est. Completion | 2017-02-24 |
Why NCT02353351 stopped before completion
NCT02353351 is an observational study that tracks outcomes without assigning an intervention. The registered 602 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which atrial septal occluder is the first listed.
NCT02353351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02353351 about?
NCT02353351 is a clinical study titled "ADVANCE ASO AMPLATZER™ Atrial Septal Occluder Post Market Surveillance Study". Prospective, multicenter, case-cohort study.To identify potential risk factors associated with the occurrence of erosion due to implantation of the AMPLATZER™ Septal Occluder (ASO.)
What is the current status of trial NCT02353351?
This trial is currently terminated. The enrollment target is 602 participants. The study started on 2015-01-19. Estimated completion is 2017-02-24.
What interventions are being tested in trial NCT02353351?
The interventions under investigation include: atrial septal occluder (DEVICE).
Who is sponsoring clinical trial NCT02353351?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI